Filtern
Volltext vorhanden
- ja (28)
Gehört zur Bibliographie
- ja (28)
Dokumenttyp
Schlagworte
- breast cancer (11)
- 3D printing (4)
- gynecology (4)
- ovarian cancer (4)
- education (3)
- teaching (3)
- BRENDA (2)
- ECMO-Therapie (2)
- Metastatic breast cancer (2)
- VEGF (2)
Institut
- Frauenklinik und Poliklinik (28)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (6)
- Theodor-Boveri-Institut für Biowissenschaften (3)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für Virologie und Immunbiologie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Kinderklinik und Poliklinik (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Institut für Geographie und Geologie (1)
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.